A Drug-Drug Interaction Study Evaluating the Combination of IDX320 and IDX184 in Healthy Subjects

2014-08-27 03:12:24 | BioPortfolio


This study is designed to evaluate the potential for a pharmacokinetic (PK) drug-drug interaction between IDX320 and IDX184 and to assess the safety and tolerability when the two drugs are administered in combination in healthy subjects.

Study Design

Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Chronic Hepatitis C


IDX320 and IDX184, IDX184 and IDX320


United States




Idenix Pharmaceuticals

Results (where available)

View Results


Published on BioPortfolio: 2014-08-27T03:12:24-0400

Clinical Trials [1571 Associated Clinical Trials listed on BioPortfolio]

Double-Blind, Dose-Escalation Study of IDX184 in Chronic Hepatitis C Treatment-Naïve Subjects

This is a proof-of-concept study which will provide data about the safety and antiviral activity of several doses of the investigational drug IDX184 given for 3 days in treatment-naive HCV...

Single-Dose Escalation Study of IDX184 in Healthy Volunteers (MK-2355-002)

The purpose of this study is to obtain single dose safety and pharmacokinetic (PK) data of IDX184 in humans. No formal hypotheses are to be tested in this study.

Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin

This study will assess short term safety, antiviral activity and pharmacokinetics (PK) of IDX184 in combination with Peg-interferon (IFN)/Ribavirin (RBV). These data will guide dose selec...

A Open-label Study to Evaluate the Relative Bioavailability of Samatasvir (IDX184) and Food Effect in Healthy Male Participants (MK-2355-006)

The purpose of this study is to: - Assess the relative bioavailability of 2 oral formulations of samatasvir (capsule and tablet prototype test formulation) - Compare the...

Study on Second Stage Follow-up of Therapeutic Hepatitis B Vaccine in Treating Chronic Hepatitis B Patients

Evaluation εPA-44 treatment of chronic hepatitis B patients with 144 weeks of efficacy and safety Provide the basis for determining dosage regimen of phase Ⅲ clinical trials

PubMed Articles [7134 Associated PubMed Articles listed on BioPortfolio]

Mortality among Patients with Chronic Hepatitis B (CHB) Infection: the Chronic Hepatitis Cohort Study (CHeCS).

According to death certificates, approximately 1800 persons die from hepatitis B annually in the United States (US); however, this figure may underestimate the true mortality from chronic hepatitis B ...

Deep sequencing identifies hepatitis B virus core protein signatures in chronic hepatitis B patients.

We aimed to identify HBc amino acid differences between subgroups of chronic hepatitis B (CHB) patients.

Clinical and laboratory characteristics of hepatitis d in Republic of Sakha (Yakutia).

Inrtroduction: The epidemiological situation for hepatitis D has changed significantly. Reduced population authors infection due to a sharp decline in hospitalizations from Central Asia regions, the C...

Comparing monovalent and combination hepatitis B vaccine outcomes in children delivered by mothers with chronic hepatitis B.

We compared the vaccine effectiveness of monovalent and combination hepatitis B vaccine regimens in infants born to chronic hepatitis B carrier mothers.

Chronic Hepatitis B Increases Liver-Related Mortality of Patients With Acute Hepatitis E: A Territorywide Cohort Study From 2000 to 2016.

The epidemiology of acute hepatitis A and E has been changing over the last 2 decades. The impact of concomitant chronic hepatitis B (CHB) on clinical outcomes remains unclear. We aimed to evaluate th...

Medical and Biotech [MESH] Definitions

INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS.

INFLAMMATION of the LIVER with ongoing hepatocellular injury for 6 months or more, characterized by NECROSIS of HEPATOCYTES and inflammatory cell (LEUKOCYTES) infiltration. Chronic hepatitis can be caused by viruses, medications, autoimmune diseases, and other unknown factors.

INFLAMMATION of the LIVER in humans caused by HEPATITIS DELTA VIRUS in conjunction with HEPATITIS B VIRUS and lasting six months or more.

A closely related group of antigens found in the plasma only during the infective phase of hepatitis B or in virulent chronic hepatitis B, probably indicating active virus replication; there are three subtypes which may exist in a complex with immunoglobulins G.

A defective virus, containing particles of RNA nucleoprotein in virion-like form, present in patients with acute hepatitis B and chronic hepatitis. It requires the presence of a hepadnavirus for full replication. This is the lone species in the genus Deltavirus.

More From BioPortfolio on "A Drug-Drug Interaction Study Evaluating the Combination of IDX320 and IDX184 in Healthy Subjects"

Quick Search


Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Searches Linking to this Trial